Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Aveni Foundation
Children's Oncology Group
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Var2 Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Nationwide Children's Hospital
NextPoint Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
University Medical Center Groningen